Dun & Bradstreet Corp (DE) (DNB) Pops 6.84% for February 15

Equities Staff |

One of the S&P 500’s big winners for Monday February 15 was Dun & Bradstreet Corp (DE) (DNB) as the company’s stock climbed 6.84% to $95.45 on volume of 601,209 shares.

The stock opened at $91.21 and saw an intraday low of $89.76 and an intraday high of $102.23. All told, the day saw a per-share gain of $6.11. The stock’s average daily volume of 207,548 and 36.13 million shares outstanding. Dun & Bradstreet Corp (DE) now has a 50-day SMA is $99.46 and 200-day SMA is $111.94, and it has a 52-week high of $137.25 and a 52-week low of $85.99.

Dun & Bradstreet Corp is a source of commercial information and insight on businesses.

Based out of Short Hills, NJ, Dun & Bradstreet Corp (DE) has 4,900 employees and, after today’s trading, reached a market cap of $3.45 billion. The stock’s P/E Ratio is 17.7. Its P/S ratio is 2.84, P/B ratio is -2.98, and P/FCF ratio is -24.3.

For a complete fundamental analysis analysis of Dun & Bradstreet Corp (DE), check out Equities.com’s Stock Valuation Analysis report for DNB. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets

Ozobot by Evollve Inc

Ozobot is a world leader in compact super intelligent robots that entertain and educate through fun interactive gaming.

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…